ReST Therapeutics is a preclinical Biotech leveraging its successful Seed Funding to advance our proprietary drug candidate through non-clinical testing and achieve the First in Human clinical study by end of 2023.

Our Mission

ReST develops breakthrough therapies to treat complex CNS disorders, in particular, various forms of Post-Traumatic Stress Disorder (PTSD) and Alzheimer’s Disease (AD). Our first candidate is Fluoro Ethyl Nor-Memantine (FENM), a new molecule selectively targeting NMDA receptors.

Management Team

Gilles Rubinstenn

Gilles Rubinstenn

Chief Operating Officer and GM France

Life Science Entrepreneur. Former Pharmaceutical BU director of M2I.

Inventor of FENM activity. Experienced manager of strategic alliances and R&D research consortia.

Florent Perin-Dureau

Florent Perin-Dureau

Chief Medical Officer

Physician, anesthesiologist and intensivist. Former ANSM director for SNC products.

Expert in NMDAr structure and function. Specialist in regulatory affairs and clinical trial design.

Our Blog

Latest Articles

ReST Academic Parners